Humana Posts Lackluster Q3 Earnings, Updates Guidance
Article By:
Zacks Investment Research
Read
Friday, November 7, 2014 12:30 PM EDT
Humana Inc.’s third-quarter 2014 operating earnings came in at $1.85 per share, lower than the Zacks Consensus Estimate of $2.01.
In this article: HUM
DaVita Beats On Q3 Earnings, Down Y/Y; Updates Guidance
Article By:
Zacks Investment Research
Read
Friday, November 7, 2014 10:55 AM EDT
DaVita HealthCare Partners Inc. reported third-quarter 2014 adjusted operating earnings of $1.01 per share that surpassed the Zacks Consensus Estimate of 91 cents.
In this article: DVA
CareFusion Q1 Earnings, Revenues Rise And Beat Estimates
Article By:
Zacks Investment Research
Read
Friday, November 7, 2014 6:15 AM EDT
CareFusion Corporation reported adjusted earnings of 50 cents per share in first-quarter fiscal 2015.
ASH 2014 Abstracts Are About To Hit: Here Are Some Of The Names To Follow
Article By:
PropThink
Read
Thursday, November 6, 2014 8:30 AM EDT
One of the biggest events in healthcare annually, the American Society of Hematology’s annual meeting (56th!) begins on December 6, but abstracts from the conference will be released this morning. Here's a primer on the stocks to watch.
Q&A With Cell Source CEO, Itamar Shimrat – Transition From Preclinical To Human Clinical Trials
Article By:
BioMedReports
Read
Wednesday, November 5, 2014 9:59 AM EDT
Recent breakthroughs from Cell Source in Veto Cell technology, which selectively tunes immune response, may change how immunologists treat blood cancers and bone marrow transplants
In this article: CLCS
Becton, Dickinson Beats Q4 Earnings, Revenues
Article By:
Zacks Investment Research
Read
Tuesday, November 4, 2014 5:40 PM EDT
Revenues increased almost 5% to $2.20 billion, better than the Zacks Consensus Estimate of $2.16 billion.
In this article: BDX
Geron Shares Surge 25% After The Removal Of A Clinical Hold By The FDA
Article By:
Terry Chrisomalis
Read
Tuesday, November 4, 2014 10:42 AM EDT
Imetelstat, a key blood cancer drug, is taken off FDA hold and can proceed to trial.
In this article: GERN
Why The World Should Be Thanking Japan
Article By:
Bill Bonner
Read
Monday, November 3, 2014 6:57 PM EDT
Japan is going to show us that you don’t have to be a Third World kleptocracy — such as Zimbabwe — to undertake extraordinary and disastrous policies.
Pause In Rally Maintains Friday's Gains
Article By:
Declan Fallon
Read
Monday, November 3, 2014 5:35 PM EDT
Friday's breakouts were small, and vulnerable to selling and 'bull traps', but today's action stayed close to Friday's highs, keeping bulls happy.
TransTech Digest: Why Mitochondria Matter
Article By:
Patrick Cox
Read
Sunday, November 2, 2014 1:49 PM EDT
We’re beginning to understand how the "mitochondrial network" fails as we age and how this failure impacts many areas of health.
Could The Bulls Run Into Year-End?
Article By:
Chris Ciovacco
Read
Thursday, October 30, 2014 8:59 PM EDT
As noted in detail on May 14, it is always important to understand both the bullish and bearish case for stocks. While the headline number for Thursday’s GDP report was impressive, the report contained something that may keep the Fed in a market-friendly mode.
Bristol-Myers Immunotherapy Drug Impresses With Phase 2 Lung Cancer Data
Article By:
Terry Chrisomalis
Read
Thursday, October 30, 2014 8:22 PM EDT
Bristol-Myers posts outstanding results In lung cancer data using immunotherapy drug
In this article: BMY
Some Indicators Work At Tops – Others At Bottoms
Article By:
Blair Jensen
Read
Wednesday, October 29, 2014 10:05 PM EDT
I had the honor of being on a panel with JC Parets, Chris Kimble, Ryan Detrick, and Charlie Bilello at Stocktoberfest this year. They are a great group of guys with a wealth of information that should be in everyone’s daily must read list.